Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04625660 · ClinicalTrials.gov registry record · NA
Detour2 Continued Access Study
A NA study of Peripheral Artery Diseases, sponsored by Endologix.
- Completed
- Registry status
- NA
- Development phase
- 11
- Enrollment target
- 3
- Study locations
NCT04625660 is a NA study of Peripheral Artery Diseases that has completed, run by Endologix. The registered enrollment target is 11 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT04625660, a NA study of Peripheral Artery Diseases, has completed, sponsored by Endologix.
- COMPLETED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
- 3
- Study locations
Study Summary
Prospective, single-arm, multi-center, clinical investigation to continue to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.
Conditions Studied
Interventions
- DEVICE PQ Bypass System
Study Locations (3)
Connecticut
- The Vascular Experts - Old Saybrook
Illinois
- AMITA Medical Group - Elk Grove Village
Virginia
- Sentara Norfolk - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-04-07 |
| Est. Completion | 2024-05-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04625660
The ClinicalTrials.gov registry entry for NCT04625660 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endologix, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Artery Diseases appearing as the primary indexed condition, and to 1 intervention - of which PQ Bypass System is the first listed.
NCT04625660 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, Illinois, Virginia.
Frequently Asked Questions
What is clinical trial NCT04625660 about?
NCT04625660 is a clinical study titled "Detour2 Continued Access Study". Prospective, single-arm, multi-center, clinical investigation to continue to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.
What is the current status of trial NCT04625660?
This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2021-04-07. Estimated completion is 2024-05-14.
What conditions does trial NCT04625660 study?
This clinical trial studies the following conditions: Peripheral Artery Diseases.
What interventions are being tested in trial NCT04625660?
The interventions under investigation include: PQ Bypass System (DEVICE).
Who is sponsoring clinical trial NCT04625660?
This trial is sponsored by Endologix, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04625660 being conducted?
This trial has 3 study locations across Connecticut, Illinois, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.